Europe Expansion European market access is being supported by Obelis as the European Authorized Representative and MDR consultant, signaling regulatory readiness for EU deployment. Past European activity such as Italy clinical cases demonstrates interest in the SING IMT for late-stage AMD. Opportunistic sales focus should target retina centers and hospitals across Europe, leveraging MDR support, local training programs, and payer discussions to accelerate adoption and building a regional distributor and clinical collaboration network.

Leadership Transition A leadership change at the top with the CEO departure could open opportunities to re-energize the go-to-market and channel strategies. The company has an established CCO who can continue to drive commercial expansion, including international markets and physician partnerships. This timing provides a window for partner outreach to align with any new strategic priorities and ensure continuity for existing clinical programs.

Clinical Adoption The SING IMT implantable telescope is FDA-approved and targets End-Stage AMD, addressing a large unmet need and differentiating the product from conventional therapies. The company has demonstrated early clinical activity in Europe and has a dedicated clinical leadership presence, suggesting readiness to scale through retina specialists, surgical centers, and hospital-based programs; sales efforts should emphasize patient-reported outcomes and surgeon training.

Global Partnerships With Obelis serving as EU Authorized Representative and MDR consultant, Samsara Vision has a solid pathway to expand internationally. The small team size benefits from partner-enabled distribution models and service agreements; developing a formal global partner ecosystem including distributors, clinical education partners, and reimbursement liaisons could accelerate cross-border sales in Europe and beyond.

Payer Opportunity As a high-value implantable device, securing payer coverage will be critical; building a payer-focused value proposition with health economics data and real-world outcomes will be essential to secure reimbursement and broaden adoption in hospitals and clinics.